# US 5,705,159 A · Immunoreactive peptide sequence from a 43 KD human cancer antigen > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 5,705,159 A - Document ID: US5705159A - Status: Granted - Kind: A - Application number: 08/190,801 - Filed: 1994-02-01 - Granted: 1998-01-06 - Earliest claimed: 1993-08-31 - Assignees: John Wayne Cancer Institute - Inventors: Reiko F. Irie; Takanori Oka - Web page: https://patentgrep.com/patent/US5705159A ## CPC - C07K 14/4748: {Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE} - A61P 35/00: Antineoplastic agents - A61P 37/04: Immunostimulants - C07K 14/47: from mammals - C07K 16/3053: {Skin, nerves, brain} - A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) - A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53) - A61K 2039/505: {comprising antibodies} - C07K 2317/21: from primates, e.g. man - C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues - C07K 2319/00: Fusion polypeptide - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) ## Abstract A tumor associated protein has been discovered to exhibit immunoreactivity to human monoclonal antibody L92. A ten amino acid peptide segment of the protein and a fourteen amino acid peptide which contains the ten amino acid peptide has also been isolated and exhibits immunoreactivity to the same antibody. Using truncated fusion proteins, the minimum recognition site for antibody binding was determined to be four amino acids. Also disclosed are polypeptide compositions against human tumors that includes the polypeptides or protein of the present disclosure, as well as antibodies reactive with these polypeptides that may be employed directly for treatment or diagnosis. A certain embodiment of the present invention is also the DNA sequence encoding the ten amino acid peptide and the DNA encoding the fourteen amino acid peptide which also exhibits immunoreactivity to human monoclonal antibody L92 and cytotoxic T cells. ## Claims ### Claim 1 A purified polypeptide segment that includes the amino acid sequence QDLTMKYQI (seq id no:9). ### Claim 2 (depends on 1) The polypeptide of claim 1, further defined as including the amino acid sequence QDLTMKYQIF (seq id no:1). ### Claim 3 (depends on 1) The polypeptide of claim 1 further defined as comprising a molecular mass of about 43 kDa. ### Claim 4 (depends on 1, 2) The polypeptide of claim 1 or 2, further defined as having a length of less than 100 amino acids. ### Claim 5 (depends on 4) The polypeptide of claim 4, further defined as having a length of less than 50 amino acids. ### Claim 6 (depends on 5) The polypeptide of claim 5, further defined as having a length of less than 25 amino acids. ### Claim 7 (depends on 6) The polypeptide of claim 6, further defined as having a length of 10 amino acids or less. ### Claim 8 (depends on 1) The polypeptide of claim 1, further defined as including the amino acid sequence of .beta.-galactosidase or glutathione-S-transferase. ### Claim 9 (depends on 1) An antigen composition comprising an amount of a polypeptide in accordance with claim 1, effective to elicit a CTL or antibody response. ### Claim 10 (depends on 9) The antigen composition of claim 9 wherein the polypeptide is present at a concentration of between 1 mg/ml and about 10 mg/ml. ### Claim 11 (depends on 10) The antigen composition of claim 10 wherein the polypeptide is present at a concentration of about 5 mg/ml. ### Claim 12 (depends on 9) The antigen composition of claim 9 wherein said polypeptide is a component of a polyvalent melanoma cell vaccine, wherein the cells in said vaccine are rendered inviable.